PMID: 9174180Jun 1, 1997Paper

Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen

Antimicrobial Agents and Chemotherapy
H JungJ Sotelo

Abstract

A brief therapeutic regimen of praziquantel, reduced to a single day, has been effective for treatment of neurocysticercosis. To study its pharmacokinetic characteristics, levels of praziquantel in plasma were determined for eight healthy volunteers after the administration of three oral doses of 25 mg/kg of body weight given at 2-h intervals, alone and with the simultaneous administration of cimetidine. Each volunteer received both regimens in a randomized crossover design. Blood samples were taken during a period of 12 h, and praziquantel concentration was measured by high-performance liquid chromatography. Levels of praziquantel in plasma remained above 300 ng/ml during a period of 12 h; they increased 100% when cimetidine was jointly administered. Compared with other regimens, the high levels obtained and the longer duration of action seem to be advantageous in prolonging the exposure of the parasites to the drug and support previous clinical experience showing that the treatment of neurocysticercosis with praziquantel can be reduced from 2 weeks to 1 day with the drug still retaining its cysticidal properties. Moreover, simultaneous administration of praziquantel and cimetidine could improve further the efficacy of the sin...Continue Reading

References

Sep 3, 1992·The New England Journal of Medicine·V Vazquez, J Sotelo
May 1, 1990·Transactions of the Royal Society of Tropical Medicine and Hygiene·M E MandourD W Harron
Jan 1, 1990·European Neurology·P R BittencourtT V Oliveira
Aug 1, 1990·Journal of Neurology·H JungJ Sotelo
Jul 1, 1990·Acta Neurologica Scandinavica·P R BittencourtT V Oliveira
Feb 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·B EstañolT Corona
Sep 6, 1986·Lancet·G WattJ H Cross
Jan 1, 1987·European Journal of Clinical Pharmacology·D OverboschH Mattie
Apr 19, 1984·The New England Journal of Medicine·J SoteloF Rubio-Donnadieu
Jan 11, 1996·The New England Journal of Medicine·T CoronaJ Sotelo

❮ Previous
Next ❯

Citations

May 31, 2003·CNS Drugs·Terrence Riley, A C White
Apr 7, 2006·Expert Review of Anti-infective Therapy·Michael J Doenhoff, Livia Pica-Mattoccia
Dec 7, 2011·Expert Review of Clinical Pharmacology·Helgi Jung-Cook
Nov 16, 2011·Expert Opinion on Pharmacotherapy·Osvaldo Massaiti TakayanaguiVera Lucia Lanchote
Sep 28, 2018·Current Medicinal Chemistry·Charlotte M Thomas, David J Timson
Jun 12, 2019·Journal of Veterinary Pharmacology and Therapeutics·Zeynep OzdemirBunyamin Tras
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·Nelly CastroJulio Sotelo
Jul 24, 2020·Pharmacology Research & Perspectives·Nyasha Nicole KapunguRoslyn Stella Thelingwani
Sep 19, 2000·Antimicrobial Agents and Chemotherapy·N CastroH Jung
Dec 12, 2018·Clinical and Translational Science·Wilhelmina Maria BagchusOezkan Yalkinoglu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.